Dutch health technology firm Royal Philips and Belgian computer-aided diagnostics company icometrix have partnered to advance precision diagnosis in neurology with new artificial intelligence (AI)-based imaging solutions.
Both partners will deploy an AI-driven, end-to-end solution for acquiring, reading, and reporting the results of MRI brain scans. This will improve diagnosis and monitoring of neurological conditions, including Alzheimer’s and multiple sclerosis (MS).
Under the partnership, icometrix’s AI quantitative reporting software will be integrated with Philips’ BlueSeal MR scanners using the latter’s new Smart Reading capability. The combined solution is said to provide more accurate, consistent results.
The software will also be available on Philips’ healthcare informatics platform, including Philips cloud-based AI Manager.
Philips chief innovation and strategy officer Shez Partovi said: “As these innovations continue to evolve, they hold great promise for transforming the landscape of neurological care, offering hope for better management of chronic conditions like Alzheimer’s and MS.
“Our partnership with icometrix is an important step forward in the use of AI to help mitigate staff shortages, lower the cost of care, increase diagnostic confidence, and facilitate care orchestration of personalised plans for the growing number of people who are diagnosed with Alzheimer’s disease.”
In addition to icometrix’s icobrain dm software for differential dementia diagnosis, the solution features icobrain ARIA software.
The US Food and Drug Administration (FDA)-cleared and classified as computer-aided detection and diagnosis, icobrain ARIA detects and grades amyloid-related imaging abnormalities (ARIA).
This fully automated software quantifies the extent of ARIA, a potentially fatal side effect of anti-amyloid drugs.
Philips’ latest BlueSeal MR scanners come equipped with AI-based SmartExam planning and AI-accelerated SmartSpeed protocols for quick ARIA imaging.
Philips’ Smart Reading software ensures integration with icometrix’s icobrain ARIA software, delivering fast, fully automated, quantitative results for Alzheimer’s patients.
Integrated into Philips’ healthcare informatics platform, these AI-driven diagnostic and therapy monitoring tools fit into radiology MR workflows and hospital PACS systems, the Dutch health technology firm said.
icometrix CEO Wim Van Hecke said: “Our icobrain imaging AI measures are rapidly becoming the standard of care for diagnosis and monitoring of neurological conditions.
“MRI quantification is crucial to unlock precision medicine, especially in the Alzheimer’s disease care pathway, which is why our partnership with Philips is so well timed.”
Philips’ latest neuroimaging solutions and icometrix’s software for Alzheimer’s and MS will be available on the Philips BlueSeal 1.5T MR scanners and the Philips 3.0T MR portfolio.
